

PDPPL PARENTERAL DRUGS (INDIA) LTD.



JAS-ANZ




M5000712ID

AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2015

PART - I Sr. No.	Particulars	3 Months Ended		Year Ended		(Rs in Lacs)
		March 2015 Audited	December 2014 Unaudited	March 2014 Audited	March 2015 Audited	Year Ended March 2014 Audited
	Income from Operation					
1	(a) Net Sales/Income from Operations (Net of Excise Duty)	3614.56	3940.51	4047.76	17589.31	18650.54
	(b) Other Operating Income	64.35	0.44	15.42	69.68	41.15
	Total Income From Operation (Net)	3,678.91	3,940.95	4,063.18	17,658.99	18,691.69
2	Expenditure					
	a) Cost of Material Consumed	1374.96	1814.06	2395.11	8689.93	10675.04
	b) Purchase of Stock In Trade					
	c) Change in Inventories of Finished Goods, Work in Progress and Stock In trade	-459.63	-150.89	451.43	(794.83)	(120.67)
	d) Employee Benefit Expenses	455.09	481.22	561.92	1844.36	1852.29
	e) Depreciation and Amortisation Expenses	1058.70	442.12	454.88	2385.06	1769.64
	f) Other Expenditure (Any Item Exceeding 10% of the Total expenses relating to continuing operations to be shown separately)	1841.83	1392.14	2897.11	6568.73	7953.57
	Total Expenses	4270.95	3978.65	6760.45	18703.25	22129.87
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(592.04)	(37.70)	(2,697.27)	(1,044.26)	(3,438.18)
4	Other Income	0.00	0.00	0.00	0.00	0.00
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(592.04)	(37.70)	(2,697.27)	(1,044.26)	(3,438.18)
6	Finance costs	1550.43	1477.95	1398.03	5917.34	5424.19
7	Profit after Interest but before Exceptional items (5-6)	(2,142.47)	(1,515.65)	(4,095.30)	(6,961.60)	(8,862.37)
8	Exceptional items	-40.72	0.00	3359.78	(40.72)	3359.78
9	Profit / (Loss) from ordinary activities before tax	(2,183.19)	(1,515.65)	(735.52)	(7,002.32)	(5,502.59)
10	Tax Expenses	-434.08	-1343.54	192.54	-1593.84	367.54
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	(1,749.11)	(172.11)	(928.06)	(5,408.48)	(5,870.13)
12	Extraordinary items (net of tax expense) Lakhs)				0.00	0.00
13	Net Profit / (Loss) for the period (11 + 12)	(1,749.11)	(172.11)	(928.06)	(5,408.48)	(5,870.13)
14	Share of profit / (loss) of associates*					
15	Minority interest *					
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(1,749.11)	(172.11)	(928.06)	(5,408.48)	(5,870.13)
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	2981.63	2981.63	2981.63	2981.63	2981.63
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				6418.93	11827.41
19 I	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):					
	(a) Basic	(5.87)	(0.58)	(3.11)	(18.14)	(19.69)
	(b) Diluted	(5.87)	(0.58)	(3.11)	(18.14)	(19.69)
19 II	Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised):					
	(a) Basic	(5.87)	(0.58)	(3.11)	(18.14)	(19.69)
	(b) Diluted	(5.87)	(0.58)	(3.11)	(18.14)	(19.69)

* Applicable in the case of consolidated results.

Note: The classification / disclosure of items in the financial results shall be in accordance with the Schedule III of the Companies Act, 2013. Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.



CORPORATE OFFICE : SHREE GANESH CHAMBERS, A.B. ROAD, NAVLAKHA CROSSING, INDORE-452 001 (M.P.) INDIA
PHONE: 4092000, 6652000, 6652001, 6652002, 6652003 Fax: (0731) 2401052

e-mail: pdpl@pdindia.com

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), MUMBAI-400 053.

Tel.:(022) 61725900, 61725901; Fax: (022) 26333763, E-mail: pdpl_mumbai@pdindia.com,

Website: www.pdindia.com CIN: L99900MH1983PLC126481

PDPL PARENTERAL DRUGS (INDIA) LTD.



JAS-ANZ



M5000712ID

PART-II

A PARTICULARS OF SHAREHOLDING						
1	Public Shareholding					
	-No. of Shares	7,967,057	7,967,057	7,967,057	7,967,057	7,967,057
	-Percentage of shareholding	26.72%	26.72%	26.72%	26.72%	26.72%
2	Promoters and Promoter Group Shareholding **					
	a) Pledged/Encumbered					
	-No. of shares	21,849,243	1,866,666	15,076,441	21,849,243	15,076,441
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	8.54%	69.00%	100.00%	69.00%
	-Percentage of Shares (as a % of the total share capital of the Company)	73.28%	6.26%	50.56%	73.28%	50.56%
	b) Non-encumbered					
	-No. of shares	-	19,982,577	6,772,802	-	6,772,802
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	91.46%	31.00%	-	31.00%
	-Percentage of Shares (as a % of the total share capital of the Company)	-	67.02%	22.72%	-	22.72%
B	Detail of Investor Complaint	3 months ended (31.03.2015)				
	Pending at the beginning of the quarter	0				
	Received during the quarter	1				
	Disposed of during the quarter	1				
	Remaining unresolved at the end of the quarter	0				

Statement of Assets and Liabilities

Sr. No.	Particulars	31.3.2015	31.3.2014
		Audited	Audited
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share Capital	4035.42	4035.42
	(b) Reserves and Surplus	6538.07	11946.88
	Sub-total - Shareholders' funds	10573.49	15982.30
2	Share application money pending allotment	0.00	0.00
3	Minority interest *		
4	Non-current liabilities		
	(a) Long-term borrowings	32975.50	32697.43
	(b) Deferred tax liabilities (net)	1150.96	2745.05
	Sub-total - Non-current liabilities	34126.46	35442.48
5	Current liabilities		
	(a) Short-term borrowings	8130.28	6822.77
	(b) Trade payables	4991.59	2936.01
	(c) Other current liabilities	4813.72	2770.93
	(d) Short-term provisions	731.46	680.69
	Sub-total - Current liabilities	18667.05	13210.40
	TOTAL - EQUITY AND LIABILITIES	63367.00	64635.18
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	29859.29	32039.15
	(b) Non-current investments	13923.35	13964.07
	(c) Long-term loans and advances	699.93	999.93
	(d) Other non-current assets	0.64	0.64
	Sub-total - Non-current assets	44483.21	47003.79
2	Current assets		
	(a) Inventories	5060.02	4475.63

CORPORATE OFFICE : SHREE GANESH CHAMBERS, A.B. ROAD, NAVLAKHA CROSSING, INDORE-452 001 (M.P.) INDIA
PHONE: 4092000, 6652000, 6652001, 6652002, 6652003 Fax: (0731) 2401052

e-mail: pdpl@pdindia.com

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), MUMBAI-400 053.

Tel.: (022) 61725900, 61725901; Fax: (022) 26333763, E-mail: pdpl_mumbai@pdindia.com,

Website: www.pdindia.com CIN: L99999MH1983PLC126481

PDPL PARENTERAL DRUGS (INDIA) LTD.



JAS-ANZ



M5000712ID

(b) Trade receivables
(c) Cash and cash equivalents
(d) Short-term loans and advances
(e) Other current assets
Sub-total - Current assets
TOTAL - ASSETS

13070.68	11468.41
205.47	569.81
208.86	917.68
338.76	199.86
18883.79	17631.39
63367.00	64635.18

NOTES :

- 1 The above results were reviewed by statutory auditors and audit committee of the company and approved by Board of Directors in their meeting held on 30th May 2015.
- 2 The Company is engaged in the Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17).
- 3 The figures for the quarter ended March 31, 2015 and March 31, 2014 are the balancing figures between audited figures in respect of the full financial year ended March 31, 2015 and March 31, 2014 respectively and the unaudited published year to date figures upto December 31, 2014 and December 31, 2013 respectively, being the end of the third quarter of the respectively financial years, which were subjected to a limited review.
- 4 The previous year/period have been regrouped/rearranged wherever found necessary.
- 5 The standalone financial results of the company are available on the website of the company i.e. www.pdindia.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com).

Place: Indore
Date: 30th May 2015

For and on behalf of Board of Directors



Vinod Kumar Gupta
Managing Director

CORPORATE OFFICE : SHREE GANESH CHAMBERS, A.B. ROAD, NAVLAKHA CROSSING, INDORE-452 001 (M.P.) INDIA
PHONE: 4092000, 6652000, 6652001, 6652002, 6652003 Fax: (0731) 2401052

e-mail: pdpl@pdindia.com

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), MUMBAI-400 053.

Tel.: (022) 61725900, 61725901; Fax: (022) 26333763, E-mail: pdpl_mumbai@pdindia.com,

Website: www.pdindia.com CIN: L50902MH1983PLC126481



PARENTERAL DRUGS (INDIA) LTD.



JAS-ANZ



M5000712ID

AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2015

PART -1 Sr. No.	Particulars	3 Months Ended		Year Ended		(Rs in Lacs)
		March 2015	December 2014	March 2014	March 2015	March 2014
		Audited	Unaudited	Audited	Audited	Audited
1	Income from Operation					
	(a) Net Sales/Income from Operations (Net of Excise Duty)	6176.38	5811.27	5872.42	26266.92	27369.76
	(b) Other Operating Income	86.17	2.65	48.33	96.36	406.49
	Total Income From Operation (Net)	6,262.55	5,813.92	5,920.75	26,363.28	27,776.25
2	Expenditure					
	a) Cost of Material Consumed	2580.37	3608.63	4265.48	14936.95	16397.66
	b) Purchase of Stock in Trade					
	c) Change in Inventories of Finished Goods, Work in Progress and Stock in Trade	-675.05	-847.29	433.95	(2192.58)	79.88
	d) Employee Benefit Expenses	615.17	605.79	743.31	2358.09	2192.78
	e) Depreciation and Amortisation Expenses	1373.41	574.83	494.58	3097.90	1862.39
	f) Other Expenditure (Any Item Exceeding 10% of the Total expenses relating to continuing operations to be shown separately)	3245.06	1810.61	8971.74	9833.07	11342.72
	Total Expenses	7138.96	5752.57	9909.06	27933.43	31875.43
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(876.41)	(138.65)	(9,988.31)	(1,570.15)	(4,099.18)
4	Other Income	0.00	0.00	0.00	0.00	0.00
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items	(876.41)	(138.65)	(9,988.31)	(1,570.15)	(4,099.18)
6	Finance costs	1898.58	1758.34	1497.69	7025.16	6020.61
7	Profit/(Loss) from ordinary activities after finance costs but before Exceptional Items (5-6)	(2,774.99)	(1,896.99)	(5,486.00)	(8,595.31)	(10,119.79)
8	Exceptional Items	40.72	0.00	236.48	40.72	5463.59
9	Profit / (Loss) from ordinary activities before tax (7+8)	(2,815.71)	(1,896.99)	(5,249.52)	(8,636.03)	(4,656.21)
10	Tax Expenses	-712.87	-1343.54	996.62	-1872.63	-139.18
11	Net Profit / (Loss) from ordinary activities after tax (9+10)	(2,102.84)	(553.45)	(6,246.14)	(6,763.40)	(4,517.03)
12	Extraordinary Items (net of tax expense Lakhs)				0.00	0.00
13	Net Profit / (Loss) for the period (11 + 12)	(2,102.84)	(553.45)	(6,246.14)	(6,763.40)	(4,517.03)
14	Share of profit / (loss) of associates*					
15	Minority Interest *					
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(2,102.84)	(553.45)	(6,246.14)	(6,763.40)	(4,517.03)
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	2981.63	2981.63	2981.63	2981.63	2981.63
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				8070.76	16593.06
19 i	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):					
	(a) Basic	(7.05)	(1.86)	(20.95)	(22.68)	(15.15)
	(b) Diluted	(7.05)	(1.86)	(20.95)	(22.68)	(15.15)
19 ii	Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised):					
	(a) Basic	(7.05)	(1.86)	(20.95)	(22.68)	(15.15)
	(b) Diluted	(7.05)	(1.86)	(20.95)	(22.68)	(15.15)

* Applicable in the case of consolidated results.

Note: The classification / disclosure of items in the financial results shall be in accordance with the Schedule III of the Companies Act, 2013. Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.



Corporate Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) INDIA
Tel.: (0731) 6652001, 6652002, 6652003, 4092000; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) INDIA
Tel.: (022) 61725900, 61725901; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com


Website: www.pdindia.com, CIN: L99999MH1983PLC126481



PARENTERAL DRUGS (INDIA) LTD.



JAS-ANZ



M5000712ID

PART - II

A PARTICULARS OF SHAREHOLDING					
1	Public Shareholding				
	-No. of Shares	7,967,057	7,967,057	7,967,057	7,967,057
	-Percentage of shareholding	26.72%	26.72%	26.72%	26.72%
2	Promoters and Promoter Group Shareholding **				
	a) Pledged/Encumbered				
	-No. of shares	21,849,243	1,866,666	15,076,441	21,849,243
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	8.54%	69.00%	100.00%
	-Percentage of Shares (as a % of the total share capital of the Company)	73.28%	6.26%	50.56%	73.28%
	b) Non-encumbered				
	-No. of shares	-	19,982,577	6,772,802	6,772,802
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	91.46%	31.00%	31.00%
	-Percentage of Shares (as a % of the total share capital of the Company)	-	67.02%	22.72%	22.72%
B	Detail of Investor Compliant	3 months ended (31.03.2015)			
	Pending at the beginning of the quarter	0			
	Received during the quarter	1			
	Disposed of during the quarter	1			
	Remaining unresolved at the end of the quarter	0			

Statement of Assets and Liabilities

Sr. No.	Particulars	31.3.2015 Audited	31.3.2014 Audited
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share Capital	4520.42	4520.42
	(b) Reserves and Surplus	8189.82	15712.59
	Sub-total - Shareholders' funds	12710.24	20232.95
	Share application money pending allotment	0.00	0.00
3	Minority Interest *	65.04	65.04
4	Non-current liabilities		
	(a) Long-term borrowings	41228.73	42215.20
	(b) Deferred tax liabilities (net)	1473.74	3346.38
	Sub-total - Non-current liabilities	42702.47	45561.58
5	Current liabilities		
	(a) Short-term borrowings	10153.97	7398.02
	(b) Trade payables	6124.26	4472.89
	(c) Other current liabilities	5830.70	3678.33
	(d) Short-term provisions	863.44	1048.56
	Sub-total - Current liabilities	22977.37	16597.80
	TOTAL - EQUITY AND LIABILITIES	78455.12	82457.37
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	41371.21	43965.71
	(b) Goodwill on consolidation *	12870.65	13218.17
	(c) Non-current investments	1.10	2.66
	(d) Long-term loans and advances	639.27	4727.84
	(e) Other non-current assets	86.81	546.53
	Sub-total - Non-current assets	54969.04	62460.91
2	Current assets		
	(a) Inventories	8027.26	5769.31
	(b) Trade receivables	13936.67	12048.72
	(c) Cash and cash equivalents	308.36	824.31
	(d) Short-term loans and advances	690.60	1034.83
	(e) Other current assets	523.19	319.29
	Sub-total - Current assets	23486.08	19996.46
	TOTAL - ASSETS	78455.12	82457.37



Corporate Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) INDIA
Tel.: (0731) 6652001, 6652002, 6652003, 4092000; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) INDIA

Tel.: (022) 61725900, 61725901; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com

Website: www.pdindia.com, CIN: L99999MH1983PLC126481




NOTES :

- 1 The above results were reviewed by statutory auditors and audit committee of the company and approved by Board of Directors in their meeting held on 30th May 2015
- 2 The financial results of the subsidiary companies have been consolidated.
- 3 The Company is engaged in the Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17).
- 4 The figures for the quarter ended March 31, 2015 and March 31, 2014 are the balancing figures between audited figures in respect of the full financial year ended March 31, 2015 and March 31, 2014 respectively and the unaudited published year to date figures upto December 31, 2014 and December 31, 2013 respectively, being the end of the third quarter of the respectively financial years, which were subjected to a limited review.
- 5 The previous year/period have been regrouped/rearranged wherever found necessary.
- 6 The standalone financial results of the company are available on the website of the company i.e. www.pdindia.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com). The key standalone financial results are given below:

Sr. No.	Particulars	Quarter Ended		Year Ended	
		Audited	Unaudited	Audited	Audited
		31.03.2015	31.12.2014	31.03.2014	31.03.2015
1	Income from operations & other income	3,678.91	3,940.95	4,063.18	17,658.99
2	Profit/Loss before tax	(2,188.19)	(1,515.65)	(735.52)	(7,002.32)
3	Profit/Loss after tax	(1,749.11)	(172.11)	(928.06)	(5,408.48)
					(5,870.13)

For and on behalf of Board of Directors


Vinod Kumar Gupta
Managing Director

Place: Indore
Date: 30th May 2015

Corporate Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) INDIA
Tel.: (0731) 6652001, 6652002, 6652003, 4092000; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) INDIA
Tel.: (022) 61725900, 61725901; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com

Website: www.pdindia.com, CIN: L99999MH1983PLC126481

To
Board of Directors of
PARENTERAL DRUGS (INDIA) LIMITED

We have audited the quarterly financial results of Parenteral Drugs (India) Limited for the quarter ended 31st March, 2015 and the year to date results for the period 1st April, 2014 to 31st March, 2015 attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the audited financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such audited financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard as per Section 133 of the Companies Act, 2013 or by the Institute of Chartered Accountants of India and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net loss and other financial information for the quarter ended 31st March, 2015 as well as the year to date results for the period from 01st April, 2014 to 31st March, 2015.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For T.N. Unni & Co.,
Chartered Accountants



T.N. Unni
(Partner)
M. No. 14520
F.R.N. 004890C

Place of signature : Indore
Date : 30.05.2015

To
Board of Directors of
PARENTERAL DRUGS (INDIA) LIMITED

We have audited the quarterly consolidated financial results of Parenteral Drugs (India) Limited for the quarter ended 31st March, 2015 and the consolidated year to date results for the period 1st April, 2014 to 31st March, 2015, attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These consolidated quarterly financial results as well as the consolidated year to date financial results have been prepared from consolidated audited financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these consolidated financial results based on our audit of such consolidated audited financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard as per Section 133 of the Companies Act, 2013 or by the Institute of Chartered Accountants of India and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

We have audited the financial statements of 7 (seven) subsidiaries included in the consolidated quarterly financial results and consolidated year to date results, whose consolidated audited financial statements reflect total assets of Rs.78455.12 lacs as at 31.03.2015 (year to date) and 78455.12 lacs as at the quarter ended 31.03.2015 (date of quarter end); as well as the total revenue of Rs. 26363.28 lacs as at 31.03.2015 (year to date) and Rs. 6262.55 lacs as at the quarter ended 31.03.2015 (date of quarter end). These audited financial statements and other financial information have been audited by other auditors whose report(s) has (have) been furnished to us, and our opinion on the quarterly financial results and the year to date results, to the extent they have been derived from such interim financial statements is based solely on the report of such other auditors.

In our opinion and to the best of our information and according to the explanations given to us these consolidated quarterly financial results as well as the consolidated year to date results:

